Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a unique chemical structure that may result in improved tolerability and a lower incidence of sedation relative to its anticonvulsant efficacy.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years.
## Adult Dosing
* **Initial:** 10 mg/day (administered in divided doses BID).
* **Titration:** Increase at weekly intervals based on clinical response and tolerability.
* **Target/Maintenance:** 20–40 mg/day (doses >20 mg/day should be divided BID).
* **Maximum:** 40 mg/day.
## Pediatric Dosing (≥2 years)
Weight-based dosing is required:
* **Weight ≤30 kg:**
* **Initial:** 5 mg/day.
* **Max:** 20 mg/day.
* **Weight >30 kg:**
* **Initial:** 10 mg/day.
* **Max:** 40 mg/day.
* **Titration:** Increase at weekly intervals; total daily dose should be divided BID.
## Dose Adjustments
* **Hepatic Impairment:** Use caution. In Child-Pugh Class A or B, initiate at 5 mg/day and titrate slowly.
* **Renal Impairment:** No standard adjustment in mild-to-moderate impairment; use caution in severe impairment.
* **CYP2C19 Poor Metabolizers:** Exposure to the active metabolite (N-desmethylclobazam) is significantly increased. Start at 50% of the recommended starting dose and titrate cautiously.
## Contraindications
* Hypersensitivity to clobazam.
* History of severe allergic reactions to benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, pyrexia, lethargy, drooling (sialorrhea), constipation, ataxia, behavioral changes (aggression, irritability).
* **Serious:** Severe dermatological reactions (SJS/TEN), respiratory depression (especially with concomitant opioids), suicidal ideation, abuse/dependence, and withdrawal seizures upon abrupt cessation.
## Key Drug Interactions
* **Opioids:** Increased risk of profound sedation, respiratory depression, coma, and death. Avoid concomitant use unless no alternatives exist.
* **CYP2C19 Inhibitors (e.g., fluconazole, fluvoxamine):** May increase clobazam levels.
* **Strong CYP2C19 Inducers (e.g., carbamazepine, St. John’s wort):** May decrease clobazam/metabolite levels, reducing efficacy.
* **Oral Contraceptives:** Clobazam may decrease the efficacy of hormonal contraceptives (CYP3A4 induction).
## Monitoring
* **Respiratory status:** Baseline and ongoing monitoring for depression, especially if combined with other CNS depressants.
* **Behavioral:** Monitor for worsening depression, suicidal ideation, or unusual changes in behavior.
* **Dermatological:** Monitor for signs of rash or blisters; discontinue immediately if SJS/TEN is suspected.
* **Tolerance:** Counsel patients regarding the potential for loss of anticonvulsant efficacy (tolerance) after long-term use.
## Clinical Pearls
* **Tapering:** Never discontinue abruptly due to the risk of status epilepticus or severe withdrawal symptoms. Taper gradually over several weeks.
* **Administration:** Oral suspension should be shaken well. Tablets can be crushed or chewed if necessary.
* **N-desmethylclobazam:** The active metabolite has a significantly longer half-life than the parent drug; steady-state concentration is reached after 4–9 days.
* **Dosing protocol:** Consult local institutional policies, as pediatric titration schedules may vary based on seizure frequency and tolerability threshold.
***
*Disclaimer: This information is for educational purposes only. Always verify current prescribing information, package inserts, and hospital-specific protocols before prescribing or administering medication.*
